Table 4 Subgroup analysis estimating the risk of MACE associated with GnRH antagonist comparing with GnRH agonist.

From: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

GnRH antagonist vs GnRH agonist

MACE

Composite CV events

 

No of event

aHRa

(95% CI)

P value

No of event

aHR

(95% CI)

P value

Pre-existing CVD, initial staging N = 1 or M = 1

GnRH antagonist (n = 106)

34

0.98a

(0.66–1.45)

0.9071

3

0.16b

(0.04–0.38)

0.013

GnRH agonist (n = 1489)

621

   

188

   

Receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months)

GnRH antagonist (n = 286)

82

0.95

(0.74–1.22)

0.7023

15

0.30

(0.16–0.54)

<0.0001

GnRH agonist (n = 10,615)

3780

   

1637

   

Pre-existing CVD, receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months)

GnRH antagonist (n = 96)

24

0.64c

(0.39–1.05)

0.0757

3

0.12d

(0.03–0.49)

0.0032

GnRH agonist (n = 2006)

687

   

375

   
  1. aHR adjusted hazard ratio, CV cardiovascular, GnRH gonadotropin-releasing hormone, MACE major adverse cardiovascular event (ischemic heart disease, stroke, congestive heart failure or CV-related death). preexising CV risk: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.
  2. aaHRs were estimated using cox model adjusted for age, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
  3. baHRs were estimated using the Fine and Gray competing risk model adjusted for age receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
  4. caHRs were estimated using cox model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
  5. daHRs were estimated using the Fine and Gray competing risk model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
Back to article page